LONDON, ONTARIO--(Marketwire - May 07, 2008) - Critical Outcome Technologies Inc. (TSX VENTURE: COT), announced today that patents to its novel drug candidates for the treatment of Acute Myelogenous Leukemia (AML) have recently been granted by the European Patent Office. The patents have been granted under European patent numbers 1 551 824 and 1 542 989 and provide protection in a market where approximately 18,000 new cases of AML are diagnosed each year and the trend in overall incidence of AML has been gradually increasing.
